• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

William C. DeWolf, FACS, MD


  • San Francisco IF, Rojas PA, DeWolf WC, Morgentaler A.Low free testosterone levels predict disease reclassification in men with prostate cancer undergoing active surveillance.BJU Int. 2014 Feb 21.
  • Delto JC, Kacker R, Bubley G, DeWolf WC.Intravesical mitomycin therapy for stage T1 and tis high-grade squamous cell carcinoma of the bladder.Clin Genitourin Cancer. 2014 Feb;12(1):e35-6.
  • Costa DN, Bloch BN, Yao DF, Sanda MG, Ngo L, Genega EM, Pedrosa I, Dewolf WC, Rofsky NM.Diagnosis of relevant prostate cancer using supplementary cores from magnetic resonance imaging-prompted areas following multiple failed biopsies.Magn Reson Imaging. 2013 Apr 18.
  • Bloch BN, Genega EM, Costa DN, Pedrosa I, Smith MP, Kressel HY, Ngo L, Sanda MG, Dewolf WC, Rofsky NM.Prediction of prostate cancer extracapsular extension with high spatial resolution dynamic contrast-enhanced 3-T MRI.Eur Radiol. 2012 Oct;22(10):2201-10.
  • San Francisco IF, Werner L, Regan MM, Garnick MB, Bubley G, DeWolf WC.Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance.J Urol. 2011 Feb;185(2):471-6.
  • Dewolf WC.Re: Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of recurrence in patients with nonmetastatic renal cell carcinoma. Editorial comment.J Urol. 2010 Sep;184(3):878.
  • Schopperle WM, Lee JM, Dewolf WC.The human cancer and stem cell marker podocalyxin interacts with the glucose-3-transporter in malignant pluripotent stem cells.Biochem Biophys Res Commun. 2010 Jul 30;398(3):372-6.
  • Lee KS, Zeikus E, DeWolf WC, Rofsky NM, Pedrosa I.MR urography versus retrograde pyelography/ureteroscopy for the exclusion of upper urinary tract malignancy.Clin Radiol. 2010 Mar;65(3):185-92.
  • Olumi AF,Dewolf WC.The hybrid of basic science and clinical training for the urologic oncologit: Necessity or waste?.Urol Oncol. 2009 Mar-Apr;27(2):205-7.
  • Pedrosa I,Sun MR,Spencer M,Genega EM,Olumi AF,Dewolf WC,Rofsky NM.MR imaging of renal masses: correlation with findings at surgery and pathologic analysis.Radiographics. 2008 Jul-Aug;28(4):985-1003. Review.
  • Dewolf WC.Re: are doctors examining prostates in university hospital?.Eur Urol. 2008 Jun;53(6):1296-7.
  • Adey GS, Pedrosa I, Rofsky NM, Sanda MG, DeWolf WC.Lower limits of detection using magnetic resonance imaging for solid components in cystic renal neoplasms.Urology. 2008 Jan;71(1):47-51.
  • Zhang X, Zhang L, Yang H, Huang X, Otu H, Libermann TA, DeWolf WC, Khosravi-Far R, Olumi AF.c-Fos as a proapoptotic agent in TRAIL-induced apoptosis in prostate cancer cells.Cancer Res. 2007 Oct 1;67(19):9425-34.
  • Pedrosa I, Chou MT, Ngo L, H Baroni R, Genega EM, Galaburda L, DeWolf WC, Rofsky NM.MR classification of renal masses with pathologic correlation.Eur Radiol. 2008 Feb;18(2):365-75.
  • San Francisco IF, Regan MM, Dewolf WC, Olumi AF.Low age adjusted free testosterone levels correlate with poorly differentiated prostate cancer.J Urol. 2006 Apr;175(4):1341-5; discussion 1345-6.
  • Ramsawh HJ, Morgentaler A, Covino N, Barlow DH, DeWolf WC.Quality of life following simultaneous placement of penile prosthesis with radical prostatectomy.J Urol. 2005 Oct;174(4 Pt 1):1395-8.
  • Hutchinson LM, Chang EL, Becker CM, Ushiyama N, Behonick D, Shih MC, DeWolf WC, Gaston SM, Zetter BR.Development of a sensitive and specific enzyme-linked immunosorbent assay for thymosin beta15, a urinary biomarker of human prostate cancer.Clin Biochem. 2005 Jun;38(6):558-71.
  • Hutchinson LM, Chang EL, Becker CM, Shih MC, Brice M, DeWolf WC, Gaston SM, Zetter BR.Use of thymosin beta15 as a urinary biomarker in human prostate cancer.Prostate. 2005 Jul 1;64(2):116-27.
  • Zhang X, Jin TG, Yang H, DeWolf WC, Khosravi-Far R, Olumi AF.Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer.Cancer Res. 2004 Oct 1;64(19):7086-91.
  • San Francisco IF, DeWolf WC, Peehl DM, Olumi AF.Expression of transforming growth factor-beta 1 and growth in soft agar differentiate prostate carcinoma-associated fibroblasts from normal prostate fibroblasts.Int J Cancer. 2004 Nov 1;112(2):213-8.
  • San Francisco IF, Regan MM, Olumi AF, DeWolf WC.Percent of cores positive for cancer is a better preoperative predictor of cancer recurrence after radical prostatectomy than prostate specific antigen.J Urol. 2004 Apr;171(4):1492-9.
  • George DJ, Regan MM, Oh WK, Tay MH, Manola J, Decalo N, Duggan S, Dewolf WC, Kantoff PW, Bubley GJ.Radical prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate cancer.Urology. 2004 Feb;63(2):327-32.
  • Spentzos D, Mantzoros C, Regan MM, Morrissey ME, Duggan S, Flickner-Garvey S, McCormick H, DeWolf W, Balk S, Bubley GJ.Minimal effect of a low-fat/high soy diet for asymptomatic, hormonally naive prostate cancer patients.Clin Cancer Res. 2003 Aug 15;9(9):3282-7.
  • Ung JO, San Francisco IF, Regan MM, DeWolf WC, Olumi AF.The relationship of prostate gland volume to extended needle biopsy on prostate cancer detection.J Urol. 2003 Jan;169(1):130-5.
  • Bubley GJ, Balk SP, Regan MM, Duggan S, Morrissey ME, Dewolf WC, Salgami E, Mantzoros C.Serum levels of insulin-like growth factor-1 and insulin-like growth factor-1 binding proteins after radical prostatectomy.J Urol. 2002 Nov;168(5):2249-52.
  • Gollob JA, Upton MP, DeWolf WC, Atkins MB.Long-term remission in a patient with metastatic collecting duct carcinoma treated with taxol/carboplatin and surgery.Urology. 2001 Dec;58(6):1058.
  • Hoffman MA, DeWolf WC, Morgentaler A.Is low serum free testosterone a marker for high grade prostate cancer?.J Urol. 2000 Mar;163(3):824-7.
  • Grégoire M, Schopperle WM, DeWolf WC.Distinct glycoforms of a tumor specific glycoprotein, gp200, in human testis and testicular tumors.J Urol. 1995 Jul;154(1):275-7.
  • Morgentaler A, DeWolf WC.A self-expanding prostatic stent for bladder outlet obstruction in high risk patients.J Urol. 1993 Nov;150(5 Pt 2):1636-40.
  • Schopperle WM, Armant DR, DeWolf WC.Purification of a tumor-specific PNA-binding glycoprotein, gp200, from a human embryonal carcinoma cell line.Arch Biochem Biophys. 1992 Nov 1;298(2):538-43.
  • Rukstalis DB, Bubley GJ, Donahue JP, Richie JP, Seidman JG, DeWolf WC.Regional loss of chromosome 6 in two urological malignancies.Cancer Res. 1989 Sep 15;49(18):5087-90.
  • Rukstalis DB, DeWolf WC.Molecular biological concepts in the etiology of testicular and other urologic malignancies.Semin Urol. 1988 Aug;6(3):161-70.
  • DeWolf WC, Carroll PG, Yunis EJ.The genetics of PLT response. I. Methodology for optimal PLT discrimination.J Immunol. 1979 Mar;122(3):860-5.
  • DeWolf WC, Lange PH, Einarson ME, Yunis EJ.HLA and testicular cancer.Nature. 1979 Jan 18;277(5693):216-7.
  • Gonzalez R, Dewolf WC.The artificial bladder sphincter AS-721 for the treatment of incontinence in patients with neurogenic bladder.J Urol. 1979 Jan;121(1):71-2.